Please assess the completion status of the following clinical trial:

Trial Title: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~For the idiopathic pulmonary fibrosis (IPF) Cohort~* Diagnosis of IPF within 7 years of screening~* Female and males ≥ 40 years of age~For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort~* Evidence of progressive ILD within the 24 months before screening~* Female and male ≥ 21 years of age.~Exclusion Criteria:~* Women of childbearing potential (WOCBP)~* Active Smokers~* Current malignancy or previous malignancy up to 5 years prior to screening~* History of allergy to BMS-986278 or related compounds~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPF Dose 1 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
- IPF Dose 2 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): None
- IPF Placebo + Post Treatment Follow-up or OTE (Type: PLACEBO_COMPARATOR): None
- PF-ILD Dose 1 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
- PF-ILD Dose 2 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): None
- PF-ILD Placebo + Post Treatment Follow-up or OTE (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).